Nichols & Pratt Advisers’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.63M Sell
17,247
-100
-0.6% -$15.3K 0.17% 53
2025
Q4
$2.39M Buy
17,347
+110
+0.6% +$14.4K 0.15% 58
2025
Q3
$2.21M Hold
17,237
0.14% 55
2025
Q2
$2.09M Sell
17,237
-185
-1% -$20.9K 0.14% 56
2025
Q1
$1.94M Sell
17,422
-300
-2% -$31.9K 0.13% 56
2024
Q4
$1.72M Sell
17,722
-19,625
-53% -$2.09M 0.11% 61
2024
Q3
$4.3M Sell
37,347
-455
-1% -$51.6K 0.28% 43
2024
Q2
$4.02M Sell
37,802
-5,494
-13% -$551K 0.27% 44
2024
Q1
$4.19M Sell
43,296
-2,647
-6% -$271K 0.28% 45
2023
Q4
$4.64M Sell
45,943
-5,321
-10% -$514K 0.33% 43
2023
Q3
$5.22M Sell
51,264
-9,965
-16% -$1.01M 0.4% 37
2023
Q2
$6.18M Sell
61,229
-56,952
-48% -$5.7M 0.45% 38
2023
Q1
$10.9M Sell
118,181
-39,587
-25% -$3.46M 0.84% 32
2022
Q4
$14.3M Sell
157,768
-9,708
-6% -$818K 1.15% 27
2022
Q3
$12.7M Sell
167,476
-94,695
-36% -$7.85M 1.13% 28
2022
Q2
$22.2M Sell
262,171
-20,665
-7% -$1.81M 1.81% 18
2022
Q1
$24.8M Sell
282,836
-7,311
-3% -$633K 1.8% 19
2021
Q4
$25.4M Sell
290,147
-8,580
-3% -$712K 1.75% 20
2021
Q3
$24.5M Sell
298,727
-15,649
-5% -$1.41M 1.85% 19
2021
Q2
$28.7M Sell
314,376
-1,425
-0.5% -$127K 2.16% 14
2021
Q1
$27M Sell
315,801
-7,801
-2% -$700K 2.11% 17
2020
Q4
$30.6M Sell
323,602
-6,173
-2% -$539K 2.43% 13
2020
Q3
$28.7M Sell
329,775
-8,602
-3% -$745K 2.48% 13
2020
Q2
$29.6M Sell
338,377
-3,148
-0.9% -$272K 2.64% 12
2020
Q1
$28.1M Buy
341,525
+1,865
+0.5% +$166K 2.82% 12
2019
Q4
$32.2M Sell
339,660
-30,788
-8% -$2.76M 2.64% 14
2019
Q3
$32.2M Sell
370,448
-29,139
-7% -$2.62M 2.63% 13
2019
Q2
$36.5M Sell
399,587
-61,448
-13% -$5.2M 3% 10
2019
Q1
$39.7M Sell
461,035
-893
-0.2% -$71.7K 3.34% 8
2018
Q4
$35.5M Sell
461,928
-6,102
-1% -$475K 3.33% 8
2018
Q3
$36.1M Sell
468,030
-1,033
-0.2% -$76.4K 2.99% 10
2018
Q2
$31.8M Sell
469,063
-59
-0% -$4.07K 2.84% 11
2018
Q1
$33.9M Buy
469,122
+181
+0% +$13.8K 3.09% 10
2017
Q4
$35.3M Buy
468,941
+1,256
+0.3% +$94.8K 3.06% 11
2017
Q3
$36M Sell
467,685
-2,338
-0.5% -$177K 3.22% 9
2017
Q2
$35.2M Sell
470,023
-938
-0.2% -$66.5K 3.21% 9
2017
Q1
$31.3M Buy
470,961
+1,537
+0.3% +$102K 2.89% 11
2016
Q4
$30.6M Sell
469,424
-12,700
-3% -$824K 2.89% 10
2016
Q3
$34.1M Sell
482,124
-960
-0.2% -$70K 3.13% 9
2016
Q2
$35.7M Buy
483,084
+7,935
+2% +$548K 3.24% 9
2016
Q1
$30.8M Buy
475,149
+61
+0% +$4.15K 2.85% 10
2015
Q4
$36.6M Sell
475,088
-1,479
-0.3% -$117K 3.52% 9
2015
Q3
$39.3M Sell
476,567
-1,559
-0.3% -$139K 3.94% 8
2015
Q2
$42.1M Sell
478,126
-2,299
-0.5% -$211K 3.92% 6
2015
Q1
$42.5M Buy
480,425
+1,284
+0.3% +$114K 3.87% 8
2014
Q4
$39.8M Sell
479,141
-2,188
-0.5% -$181K 3.51% 8
2014
Q3
$40.6M Sell
481,329
-6,355
-1% -$514K 3.61% 9
2014
Q2
$39.6M Sell
487,684
-3,134
-0.6% -$247K 3.43% 10
2014
Q1
$37.4M Sell
490,818
-4,860
-1% -$354K 3.38% 10
2013
Q4
$35.7M Sell
495,678
-5,470
-1% -$380K 3.36% 10
2013
Q3
$34.4M Sell
501,148
-9,101
-2% -$602K 3.46% 10
2013
Q2
$32.3M Buy
+510,249
New +$33.2M 3.38% 9

Other funds holding NVS

Nichols & Pratt Advisers's NVS Position: Q1 2026 in Review

Nichols & Pratt Advisers reduced its Novartis (NVS) stake by 0.58% in Q1 2026, selling an estimated $15.3K and leaving 17,247 shares worth $2.63M. The position accounts for 0.17% of the portfolio, ranked #53.

Nichols & Pratt Advisers first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $42.5M in Q1 2015. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Nichols & Pratt Advisers held 17,247 shares of Novartis worth $2.63M as of Q1 2026.
  • Nichols & Pratt Advisers sold 100 Novartis shares in Q1 2026, an estimated $15.3K.
  • Novartis made up 0.17% of Nichols & Pratt Advisers's portfolio in Q1 2026, its #53 holding.
  • Nichols & Pratt Advisers first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Nichols & Pratt Advisers's Novartis position peaked at $42.5M in Q1 2015.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Nichols & Pratt Advisers's 13F filing for Q1 2026, filed 29 Apr 2026.